BillionToOne

Historical price data

BillionToOne is a commercial-stage molecular diagnostics company leveraging its Quantitative Counting Templates™ (QCTs™) technology to achieve single-molecule resolution in genetic testing. Founded in 2016, the company has launched two main product lines: UNITY Complete® for comprehensive prenatal screening and the Northstar platform for oncology liquid biopsy. Having completed an upsized IPO in late 2025, BillionToOne is now a public company executing on its vision to make precise, quantitative diagnostics more accessible.

Proprietary single-molecule next-generation sequencing (smNGS) platform enabled by Quantitative Counting Templates™ (QCTs™) that allows for absolute quantification of genetic targets at the single DNA molecule level with single base-pair resolution.

2 drugs in pipeline

Total raised: $122.5M

In prenatal testing, BillionToOne competes with Natera, Roche, and Labcorp, differentiated by its single-gene recessive disorder screening. In liquid biopsy, it faces Guardant Health and Foundation Medicine, competing on its claimed superior sensitivity for low-shedding tumors. Its core QCT technology for absolute quantification is a unique differentiator against competitors using relative quantification methods.